BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35195687)

  • 1. AMP-activated protein kinase promotes breast cancer stemness and drug resistance.
    Andugulapati SB; Sundararaman A; Lahiry M; Rangarajan A
    Dis Model Mech; 2022 Jun; 15(6):. PubMed ID: 35195687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
    Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
    Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
    Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
    Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
    PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-448 inhibits stemness maintenance and self-renewal of hepatocellular carcinoma stem cells through the MAGEA6-mediated AMPK signaling pathway.
    Guo JC; Yang YJ; Zhang JQ; Guo M; Xiang L; Yu SF; Ping H; Zhuo L
    J Cell Physiol; 2019 Dec; 234(12):23461-23474. PubMed ID: 31232474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
    Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
    Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells.
    Hindupur SK; Balaji SA; Saxena M; Pandey S; Sravan GS; Heda N; Kumar MV; Mukherjee G; Dey D; Rangarajan A
    Breast Cancer Res; 2014 Aug; 16(4):420. PubMed ID: 25096718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
    Corominas-Faja B; Cufí S; Oliveras-Ferraros C; Cuyàs E; López-Bonet E; Lupu R; Alarcón T; Vellon L; Iglesias JM; Leis O; Martín ÁG; Vazquez-Martin A; Menendez JA
    Cell Cycle; 2013 Sep; 12(18):3109-24. PubMed ID: 23974095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAC1B function is essential for breast cancer stem cell maintenance and chemoresistance of breast tumor cells.
    Chen F; Gurler SB; Novo D; Selli C; Alferez DG; Eroglu S; Pavlou K; Zhang J; Sims AH; Humphreys NE; Adamson A; Campbell A; Sansom OJ; Tournier C; Clarke RB; Brennan K; Streuli CH; Ucar A
    Oncogene; 2023 Feb; 42(9):679-692. PubMed ID: 36599922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties.
    Liu S; Sun Y; Hou Y; Yang L; Wan X; Qin Y; Liu Y; Wang R; Zhu P; Teng Y; Liu M
    J Hematol Oncol; 2021 Oct; 14(1):178. PubMed ID: 34715882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
    Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
    Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
    Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
    Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
    Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
    Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
    [No Abstract]   [Full Text] [Related]  

  • 16. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
    Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
    Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
    Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling.
    Zhao Q; Liu Y; Wang T; Yang Y; Ni H; Liu H; Guo Q; Xi T; Zheng L
    Eur J Pharmacol; 2020 Oct; 884():173359. PubMed ID: 32738343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels.
    Wen S; Qin Y; Wang R; Yang L; Zeng H; Zhu P; Li Q; Qiu Y; Chen S; Liu Y; Hou Y; Tang X; Liu M; Tu G
    Cell Death Dis; 2021 May; 12(5):437. PubMed ID: 33934099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.